Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.

John Sweetenham, Klaus Hieke, Matthew Kerrigan, Paul Howard, Pamela F.M. Smartt, Ann Marie McIntyre, Sarah Townshend

Research output: Contribution to journal › Article › peer-review